Compares two treatment regimens before stem cell transplant in relapsed myeloma
Looks back at patients with relapsed myeloma given a bortezomib-bendamustine-melphalan regimen.
Plain-language title generated from the registry record
Registry title: Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Key facts
- Where
- Uppsala, SwedenSee the site
Where in Sweden
- Akademiska sjukhusetUppsala, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Uppsala University
- Trial code
- NCT06245629
- Record updated
- 29 November 2024
- Original description
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.Read full original descriptionShow less
Bortezomib-bendamustine-melphalan vs High-dose Melphalan in Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma - a Single Center Retrospective Cohort Study
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.
Inclusion: Diagnosis of first relapse after previous ASCT for multiple myeloma according to the International Myeloma Working Group; Treated with a second ASCT (ASCT2) as part of second line treatment at UUH; Conditioning at ASCT2 with bortezomib-bendamustine-melphalan or high-dose melphalan only.
Exclusion: Allogenic haematopoietic stem cell transplantation as part of first or second line therapy; Failure to meet the minimal dataset, defined as: (date of ASCT1 and ASCT2, date of start of induction treatment for relapsed myeloma prior to ASCT2, medical records from hospitalization for ASCT2, at least one follow-up visit (unless early death before first follow-up visit), date of progression and first treatment of relapsed multiple myeloma after ASCT2; Double (tandem) ASCT in first or second line treatment.